Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8638 participants
Moderate
no estimate extracted
2 studies · 8544 participants
High
Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
3 studies · 21870 participants
High
no estimate extracted
3 studies · 21870 participants
Moderate
no estimate extracted
3 studies · 21870 participants
High
Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation
3 findings from 1 review
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
no estimate extracted
1 study · 1861 participants
Low
Body‐mass index (BMI) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Height (cm) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (HRQL) · people with asthma
1 finding from 1 review
Adverse events · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations · people with asthma
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with asthma
1 finding from 1 review
Asthma symptoms · people with asthma
1 finding from 1 review
Adverse events · people with asthma
1 finding from 1 review
Health‐related quality of life (HRQL) · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbations · adults and children with exercise‐induced bronchoconstriction/asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 % drop Postexercise · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Asthma symptoms · adults and children with exercise‐induced bronchoconstriction/asthma
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Low
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to neovascular AMD compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review